Trutect wins full USDA approval for canine parvovirus

Elanco’s canine parvovirus monoclonal antibody, previously sold as CPMA and now branded Trutect, received full USDA approval in December 2025, making it the first and only USDA-approved targeted treatment for canine parvovirus. The product had initially received conditional licensure in May 2023, and its label was expanded in June 2025 to include passive immunity for puppies exposed to parvo, allowing use in both treatment and prevention settings. Elanco says real-world data from the first year of launch showed a 93% survival rate among treated puppies and an average hospital stay reduction of 1.87 days. (elanco.com)

Why it matters: For veterinary professionals, this is a meaningful shift from a parvo standard of care built almost entirely around supportive therapy. A targeted monoclonal antibody could reduce hospitalization time, ease isolation and staffing pressure, and give clinics and shelters another option for exposed puppies before they become critically ill. The underlying evidence base is also growing: a 2024 JAVMA study supporting licensure found that early administration prevented mortality after experimental challenge, and a 2025 study on prophylactic use highlighted an important operational consideration, that passive antibody can temporarily interfere with modified-live parvo vaccination similarly to maternally derived antibodies. (pubmed.ncbi.nlm.nih.gov)

What to watch: Watch for how quickly Trutect is incorporated into everyday GP, ER, and shelter protocols, and for updated guidance on timing of vaccination after prophylactic use. (my.elanco.com)